Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

While experts welcomed Mounjaro's launch, they stressed the importance of responsible prescribing to prevent misuse of the drug used for the treatment of type 2 diabetes and obesity.

There are so many false promises online when it comes to losing weight. Here are my top weight loss technologies that ...

According to a recent study, tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.